Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,465 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00560235 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | completed | Phase 1 / Phase 2 | 138 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00309023 | Study of BMS-663513 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 115 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 12, 2015 | clinicaltrials |
| NCT00550017 |
| A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2) |
| terminated |
| Phase 1 / Phase 2 |
| 39 |
| Bristol-Myers SquibbINDUSTRY |
| 3 |
| Oct 12, 2015 |
| clinicaltrials |
| NCT01548482 | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01628471 | MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 20 | Uman PharmaINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT00364676 | Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 1 | 67 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Sep 22, 2015 | clinicaltrials |
| NCT02321293 | A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC(CURCUMIN) | unknown | Phase 1 | 20 | Lady Davis InstituteOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01489722 | Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients | terminated | Phase 1 | 55 | AstraZenecaINDUSTRY | 2 | Aug 11, 2015 | clinicaltrials |
| NCT00510250 | A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer | completed | Phase 1 / Phase 2 | 13 | University Health Network, TorontoOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00800059 | Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma(TMI-ASCT) | unknown | Phase 1 / Phase 2 | 27 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00045513 | Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00052494 | Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 9 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00101153 | Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00121277 | Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 28 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00126620 | Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 17 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00609934 | Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | completed | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT01163903 | Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours | completed | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Jul 15, 2015 | clinicaltrials |
| NCT00618722 | Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat(ATX-101) | completed | Phase 1 / Phase 2 | 85 | Kythera BiopharmaceuticalsINDUSTRY | 3 | Jul 14, 2015 | clinicaltrials |
| NCT00706316 | Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer(NPC-CTL) | completed | Phase 1 | 5 | University Health Network, TorontoOTHER | 1 | Jul 10, 2015 | clinicaltrials |
| NCT01116843 | Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment | completed | Phase 1 / Phase 2 | 13 | University Health Network, TorontoOTHER | 1 | Jul 10, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 | clinicaltrials |
| NCT00798252 | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | completed | Phase 1 | 111 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 7, 2015 | clinicaltrials |
| NCT01725191 | Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2015 | clinicaltrials |
| NCT00372437 | A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine | completed | Phase 1 / Phase 2 | 47 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT01126814 | A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 35 | University Health Network, TorontoOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01334099 | Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients | terminated | Phase 1 | 6 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01271972 | Study of Nesvacumab (REGN910/ SAR307746) | completed | Phase 1 | 53 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 16, 2015 | clinicaltrials |
| NCT00453427 | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas(ACCAPELA) | completed | Phase 1 / Phase 2 | 20 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00020111 | Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 3 | Apr 29, 2015 | clinicaltrials |
| NCT01332786 | Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia | completed | Phase 1 | 27 | University Health Network, TorontoOTHER | 2 | Apr 15, 2015 | clinicaltrials |
| NCT01673737 | A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer | completed | Phase 1 | 75 | SanofiINDUSTRY | 2 | Apr 10, 2015 | clinicaltrials |
| NCT01555242 | A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas | completed | Phase 1 | 22 | Omnitura Therapeutics, Inc.INDUSTRY | 1 | Apr 8, 2015 | clinicaltrials |
| NCT02065960 | Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer(ARTEMIS) | unknown | Phase 1 | 32 | Juravinski Cancer CenterOTHER | 1 | Mar 31, 2015 | clinicaltrials |
| NCT01688960 | Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies | completed | Phase 1 | 48 | Regeneron PharmaceuticalsINDUSTRY | 2 | Mar 17, 2015 | clinicaltrials |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | Emory UniversityOTHER | 2 | Mar 10, 2015 | clinicaltrials |
| NCT01715168 | A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer | unknown | Phase 1 | 40 | Azaya Therapeutics, Inc.INDUSTRY | 2 | Jan 15, 2015 | clinicaltrials |
| NCT00323934 | Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 42 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jan 8, 2015 | clinicaltrials |
| NCT00324129 | A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes | completed | Phase 1 | 29 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jan 8, 2015 | clinicaltrials |
| NCT00324194 | A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 25 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jan 8, 2015 | clinicaltrials |
| NCT00351975 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | completed | Phase 1 | 51 | Seagen Inc.INDUSTRY | 2 | Dec 18, 2014 | clinicaltrials |
| NCT00438828 | Dexamethasone for the Prophylaxis of Pain Flare Study | completed | Phase 1 | 61 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials